Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia

ZHANG Zhuo-rui; SUN Chang-you; YANG Jun-feng; YANG Mao-lin; XIAO Min-hui

doi:10.13422/j.cnki.syfjx.2015090192

您当前的位置：

首页 >

文章列表页 >

Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia

更新时间：2024-01-04

- Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 9, Pages: 192-195(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015090192
  CLC： R697.3
- Published：2015
- 稿件说明：
移动端阅览
ZHANG Zhuo-rui, SUN Chang-you, YANG Jun-feng, et al. Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(9): 192-195.
DOI：

ZHANG Zhuo-rui, SUN Chang-you, YANG Jun-feng, et al. Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(9): 192-195. DOI： 10.13422/j.cnki.syfjx.2015090192.

摘要

目的: 观察桂附地黄丸联合坦洛新对良性前列腺增生(BPH)(肾阳虚证)疾病进展的影响. 方法: 将116例BPH患者采用随机按数字表法分为西药组56例和观察组60例.西药组口服盐酸坦洛新缓释胶囊

0.2 mg/次

1次/晚;观察组在西药组治疗的基础上加用桂附地黄丸

6 g/次

2次/d

口服.两组疗程均为12周.进行国际前列腺症状评分(I-PSS)

肾阳虚证、排尿症状对生活质量(QOL)评分;测量残余尿量(PVR)

最大尿流率(Qmax)和平均尿流率(Qave);采用B超检测前列腺大小和质量;记录夜尿次数

以上指标治疗前后各评价1次. 结果: 观察组临床疗效总有效率为91.66%

西药组为76.78%

观察组优于西药组(P <0.05);治疗后观察组I-PSS

肾阳虚证和QOL评分均比西药组低(P <0.01);治疗后观察组PVR少于西药组(P <0.01)

观察组Qmax和Qave高于西药组(P <0.01);治疗后观察组前列腺大小和前列腺质量均比治疗前减少

并P <0.01);治疗后观察组夜尿次数少于西药组(P <0.01). 结论: 桂附地黄丸联合坦洛新治疗BPH(肾阳虚证)患者

能改善下尿路症状

提高患者生活质量

改善了BPH临床进展的高危因素

值得进一步的研究.

Abstract

Objective: To observe the effect of Guifu Dihuang pills combined tamsulosin hydrochloride sustained release capsules in treating benign prostatic hyperplasia (BPH) disease of kidney-yang deficiency syndrome. Method: One hundred and sixteen BPH patients were randomly divided into the control group (56 cases) and the observation group (60 cases) via a digital method. Patients in the control group received 0.2 mg tamsulosin hydrochloride sustained release capsules orally once every night. Based on the therapy of the control group

patients in the observation group added 6 g Guifu Dihuang pills orally twice daily. All patients in two groups received 12 weeks of treatment. International prostate symptom scores (I-PSS)

kidney-yang deficiency syndrome scores

and quality of life (QOL) scores caused by urination symptom were assessed. Moreover

post-void residual urine volumes (PVR)

the maximal urinary flow rates(Qmax) and average urinary flow rates (Qave) were measured. Prostate size and quality were tested through type-B ultrasonic. Enuresis nocturia frequencies were recorded. Result: The total curative effect in the observation group was 91.66%

which was superior to 76.78% in the control group (P <0.05). Scores of I-PSS

kidney-YANG deficiency syndrome

QOL in the observation group were less than those in the control group (P <0.01). The PVR in the observation group was lower (P <0.01)

the Qmax and Qave were higher than those in the control group (P <0.01). After therapy

prostate size and quality decreased as compared with the control group (P <0.01). Frequencies of enuresis nocturia were less than those in the control group (P <0.01). Conclusion: Guifu Dihuang pills combined tamsulosin could ameliorate lower urinery-tract syndrom

improve patients' QOL and ameliorate risk factors of clinical progression in treating BPH patients with kidney-yang syndrome

and it is worthy of further study.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Kelong Capsules in Treatment of Benign Prostatic Hyperplasia Based on Nrf2 Pathway and Macrophage Activation

Clinical Effect of Xiaozhi Hugan Capsules in Treatment of Patients with Non-alcoholic Steatohepatitis and Its Impact on Serum IL-6 and MCP-1

Cyclocarya paliurus Polysaccharide Inhibits Benign Prostatic Hyperplasia by Reducing 5α-Reductase 2

Clinical Efficacy and Safety of Qingyusan Capsules in Treatment of Ulcerative Colitis with Syndrome of Large Intestine Dampness-heat

Clinical Efficacy of Fuzheng Huaji Longbi Decoction in Treating Benign Prostatic Hyperplasia with Syndrome of Healthy Qi Deficiency and Blood Stasis

Related Author

SONG Guanhui

FAN Danping

LI Yan

LIU Hong

PAN Jinghua

WANG Shaojun

FAN Xiang

SUN Jian

Related Institution

Beijing University of Chinese Medicine

Experimental Research Center，China Academy of Chinese Medical Sciences

The First Clinical Medical College of Shaanxi University of Chinese Medicine

The First Clinical Medical College， Henan University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰